LataMed AI Corp. (OTC: LMED), a digital health and artificial intelligence technology company focused on telehealth infrastructure and healthcare analytics for emerging markets, announced it expects to formally submit a corporate action request to FINRA today seeking approval of a proposed five-for-one forward stock split. The proposal includes proportional increases in the company's authorized common and preferred stock.
The forward split would apply to all issued and outstanding shares of common stock and outstanding preferred stock designations, including the Series C Voting Preferred Stock. The company stated that the split is intended to support long-term operational scalability, strategic flexibility, capitalization planning, and future growth initiatives as it advances telehealth infrastructure deployment, healthcare analytics integration, regulatory progression, and commercialization throughout Latin America and other emerging markets.
LataMed AI emphasized that the corporate action does not involve any debt restructuring, recapitalization, or reduction in shareholder ownership percentages. No fractional shares are expected to be issued; any fractional interests would be rounded up to the nearest whole share pursuant to approved Board resolutions. Management noted that the forward split is part of a broader effort to align its capital structure with its ongoing transition into digital healthcare infrastructure and AI-driven telehealth operations.
Dr. Kevin Rodan Levy, Chief Executive Officer, stated: "As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives as we continue building our healthcare technology platform."
The company recently announced commencement of initial operational activities for its telehealth platform in Venezuela following regulatory authorization from the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS). The proposed stock split remains subject to FINRA review and approval, completion of applicable regulatory processing, and final corporate implementation procedures. No assurance can be provided regarding timing or ultimate effectiveness.
For more information, visit https://latamed.ai or review the company's SEC filings at www.sec.gov.
